Endocrine Function During Deferasirox Therapy

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

NCT00564941 ·Status: COMPLETED ·Phase: PHASE4

Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox

NCT03358498 ·Status: UNKNOWN

Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet

NCT02993224 ·Status: COMPLETED ·Phase: PHASE2

Efficacy Study of the Use of Sequential DFP-DFO Versus DFP

NCT00733811 ·Status: COMPLETED ·Phase: PHASE4

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

NCT01459718 ·Status: TERMINATED ·Phase: PHASE2

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study

NCT00873041 ·Status: COMPLETED ·Phase: PHASE2

Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia

NCT01496963 ·Status: COMPLETED

"Iron Overload and Endocrinological Diseases"

NCT06137079 ·Status: RECRUITING

Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox Therapy

NCT01874405 ·Status: COMPLETED

Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias

NCT00061763 ·Status: COMPLETED ·Phase: PHASE2

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

NCT01709032 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)

NCT01996683 ·Status: UNKNOWN ·Phase: NA

This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

NCT01250951 ·Status: COMPLETED ·Phase: PHASE4

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

NCT00171301 ·Status: COMPLETED ·Phase: PHASE4

Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec

NCT00879242 ·Status: COMPLETED ·Phase: PHASE2

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

NCT03637556 ·Status: COMPLETED ·Phase: PHASE2

Evaluating People With Thalassemia: The Thalassemia Longitudinal Cohort (TLC) Study

NCT00661804 ·Status: COMPLETED

Changes in Pituitary Iron and Volume With Deferasirox

NCT01376622 ·Status: COMPLETED

Post Hematopoietic Stem Cell Transplantation

NCT01610297 ·Status: COMPLETED ·Phase: PHASE4

Atrial Fibrillation in Beta-Thalassemia

NCT05508932 ·Status: RECRUITING

Assessment of Nutritional Status and Role of Insulin-like Growth Factor-1 in Children

NCT05529550 ·Status: COMPLETED

Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients

NCT02198508 ·Status: COMPLETED ·Phase: NA

Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis

NCT00000595 ·Status: COMPLETED ·Phase: PHASE2

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

NCT00379483 ·Status: COMPLETED ·Phase: PHASE2

Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major

NCT00480506 ·Status: COMPLETED